SNORD71: SNORD71 is a small nucleolar RNA (snoRNA) that has been implicated in various diseases, including T-cell lymphoma and chronic B-cell lymphocytic leukemia (CLL) [PMC8389557] [PMC8677010] [PMC9219770]. It has been found to be overexpressed in cases of T-cell lymphoma with a favorable outcome [PMC8677010]. In CLL, SNORD71, along with other snoRNAs such as SNORD35b and SNORD116-11, showed differential expression compared to normal B-cells [PMC9219770]. SNORD71 has also been identified as highly expressed in HMEC and HCC1954 cells [PMC4338251]. In cancer samples, sd/miR-768-5p, which is derived from SNORD71, was significantly downregulated [PMC9404758]. Additionally, snoRNA HBII-239 (SNORD71)-derived miRNA precursors have been found to bind to fibrillarin protein [PMC5765200]. Although specific snoRNA signatures associated with CLL outcome have not been identified, a snoRNA profile including SNORD35B and SNORD116-25 was able to discriminate between healthy B-cells and leukemic cells in CLL samples [PMC8629011]. Furthermore, the human Y-box binding protein 1 (YB-1) has been shown to bind SNORD71 and associate with hnRNP A1 protein [PMC8467515]. Conservation of the SNORD71 sequence has been observed across vertebrates including humans [PMC5579392]. In peripheral T-cell lymphoma, overexpression of SNORD71 is associated with a favorable outcome [PMC4627319]. Additionally, other small nucleolar RNAs such as SNORA80 have shown an association with progression from smoldering to symptomatic multiple myeloma (MM) [PMC3766210]. SNORD71 has also been identified as a transcript specific to MCF7 cells [PMC8713755]. Overall, SNORD71 has been implicated in various diseases and has potential clinical relevance as a biomarker and prognostic marker in cancer.